Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42158440/
HER2-low breast cancer, defined as immunohistochemistry (IHC) 1+ or 2+ with negative in situ hybridization (ISH), has emerged as a clinically relevant therapeutic subgroup. We report the case of a...
Case highlights disitamab vedotin (RC-48) activity in heavily pretreated HER2-low metastatic breast cancer, demonstrating regression of cutaneous and visceral metastases while emphasizing dynamic HER2 status changes and the importance of repeat biopsy.
Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40412427/
Cancer Research UK, GE Healthcare, and Bayer Healthcare.
BRAID interim results showed abbreviated MRI and contrast-enhanced mammography detected substantially more and smaller invasive breast cancers than automated whole-breast ultrasound in women with dense breasts, supporting supplemental imaging to improve early cancer detection.
Complete response in a patient with metastatic metaplastic breast cancer treated with immune checkpoint inhibitor and chemotherapy: A case report and a review of the literature - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40905880/
Metaplastic breast cancer (MpBC) is a rare subtype of breast cancer characterized by poor prognosis and lack of treatment guidance. It is notably resistant to conventional chemotherapy. Currently, immunotherapy is...
This case report describes complete response in metastatic metaplastic triple-negative breast cancer treated with chemotherapy plus immune checkpoint inhibition, highlighting immunotherapy’s potential efficacy in this rare, chemotherapy-resistant malignancy.
Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40884047/
URL: https://www.clinicaltrials.gov; Unique identifier: NCT03760588.
Sacubitril/valsartan did not significantly prevent LVEF decline during breast cancer therapy, though it improved strain and biomarkers, suggesting partial cardioprotection without clear impact on primary cardiac dysfunction endpoint.
Respiratory viral infections awaken metastatic breast cancer cells in lungs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40739350/
Breast cancer is the second most common cancer globally, with most deaths caused by metastatic disease, often following long periods of clinical dormancy 1 . Understanding the mechanisms that disrupt...
Study shows respiratory viral infections trigger inflammation that reactivates dormant breast cancer cells in lungs, promoting rapid metastatic growth via IL-6–dependent mechanisms, with human data confirming increased metastasis and mortality risk.